secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001654954-25-002744
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica reports record Q4 revenue $7.9M, full year $27.3M; net loss narrows to $7.2M
--------------------------------------------------------------------------------

- Q4 2024 revenue $7.9M (+8% YoY); full year $27.3M, also up 8% from 2023.
- Gross margin 70.3% for Q4 and 70.0% for full year, at high end of 65-70% guidance.
- Net loss improved to $7.2M in Q4 from $22.4M a year ago; full year net loss $47.0M vs $34.5M.
- Diagnostics segment revenue surged 109% YoY in Q4 driven by TRUFORMA and VETGuardian adoption.
- Cash, equivalents and securities $71.4M; adjusted non-GAAP EBITDA loss $20.2M for full year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495425002744/0001654954-25-002744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495425002744/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-002744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer